Mpox: Vaccination
Lords · Question HL1489 · Tabled 10 Oct 2024 · Department of Health and Social Care · Official record
Answered 18 Oct 2024
Question
Asked by Lord Cashman
To ask His Majesty's Government whether, since the PALM007 study has shown the antiviral ingredient tecovirimat does not always reduce the duration of mpox lesions, a mixed stockpile of antiviral agents for mpox is being considered.
Answer
Answered by Baroness Merron, 18 Oct 2024
In addition to the ongoing efforts to control Mpox clade IIb in the United Kingdom, there is widespread planning underway across the Government, including work by the Department, the UK Health Security Agency, and the National Health Service, to prepare f...